Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07414979 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT07414979: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT07414979 is a Phase 1 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07414979, a Phase 1 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The proposed study is a single arm Phase I trial aimed at treating up to 6 HLA-A\*0201+ and HLA-A\*24 02+ individuals with leptomeningeal disease from metastatic melanoma.
Interventions
- DRUG CD8+T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2026-08-31 |
| Est. Completion | 2030-03-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07414979
The ClinicalTrials.gov registry entry for NCT07414979 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CD8+T cells is the first listed.
NCT07414979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07414979 about?
NCT07414979 is a clinical study titled "Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma". The proposed study is a single arm Phase I trial aimed at treating up to 6 HLA-A\*0201+ and HLA-A\*24 02+ individuals with leptomeningeal disease from metastatic melanoma.
What is the current status of trial NCT07414979?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2026-08-31. Estimated completion is 2030-03-22.
What interventions are being tested in trial NCT07414979?
The interventions under investigation include: CD8+T cells (DRUG).
Who is sponsoring clinical trial NCT07414979?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.